MARKET

KURA

KURA

Kura Oncology Inc
NASDAQ
8.96
+0.45
+5.29%
After Hours: 8.97 +0.01 +0.11% 19:49 03/06 EST
OPEN
8.28
PREV CLOSE
8.51
HIGH
8.97
LOW
8.19
VOLUME
1.99M
TURNOVER
--
52 WEEK HIGH
12.49
52 WEEK LOW
5.41
MARKET CAP
779.68M
P/E (TTM)
-2.8190
1D
5D
1M
3M
1Y
5Y
1D
Kura Oncology (KURA) Receives a Hold from Guggenheim
TipRanks · 14h ago
Kura Oncology price target raised to $30 from $29 at BofA
TipRanks · 1d ago
Kura Oncology Price Target Cut to $36.00/Share From $38.00 by Wedbush
Dow Jones · 1d ago
Kura Oncology Is Maintained at Outperform by Wedbush
Dow Jones · 1d ago
Wedbush Maintains Outperform on Kura Oncology, Lowers Price Target to $36
Benzinga · 1d ago
Kura Oncology price target lowered to $36 from $38 at Wedbush
TipRanks · 1d ago
BRIEF-Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Reuters · 1d ago
Kura Oncology Reports Inducement Stock Option Grants for Four New Employees
Reuters · 1d ago
More
About KURA
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a FTI, is being evaluated in a Phase I dose-escalation trial as a monotherapy and in combination with targeted therapies.

Webull offers Kura Oncology Inc stock information, including NASDAQ: KURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KURA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KURA stock methods without spending real money on the virtual paper trading platform.